<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107584</url>
  </required_header>
  <id_info>
    <org_study_id>HTN2019</org_study_id>
    <nct_id>NCT04107584</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Plasma Biomarkers Among Patients With Hypertension</brief_title>
  <acronym>BIOMS-HTN</acronym>
  <official_title>Prognostic Value of Plasma Biomarkers Among Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Institute of Heart, Lung and Blood Vessel Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Institute of Heart, Lung and Blood Vessel Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is the most important risk factor for cardiovascular and cerebrovascular
      diseases，and also a substantial public health problem. The purpose of the study is to
      investigate the association between plasma biomarkers and adverse outcomes in patients with
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary mortality of hypertension</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The incidence rate of primary mortality of hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes of heart</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The incidence rate of left ventricular hypertrophy, myocardial infarction, congestive heart failure, and arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes of brain</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The incidence rate of stroke (include cerebral hemorrhage and cerebral ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes of kidney</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The incidence rate of hypertensive renal injure and end-stage renal disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes of eyes</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The incidence rate of hypertensive eye injure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients with hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  In accordance with the diagnosis of hypertension (BP≥140/90mmHg)

        Exclusion Criteria:

          -  The exclusion Criteria for the study program were as follows:

        Pregnancy, history of heart failure or left ventricular ejection fraction less than 40%,
        myocardial infarction within one month, percutaneous transluminal coronary angioplasty or
        coronary artery bypass grafting, cerebrovascular disease, severe liver disease, severe
        chronic renal failure (eGFR less than 30 mL/min/1.73 m2) in the past three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Du, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yulin Li, PhD</last_name>
    <phone>0086-010-64456453</phone>
    <email>lyllyl_1111@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulin Li, PhD</last_name>
      <email>lyllyl_1111@163.com</email>
    </contact>
    <investigator>
      <last_name>Jie Du, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

